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STATE-OF-THE-ART REVIEW AND
COMMENTARYSTATE-OF-THE-ART REVIEW AND COMMENTARY951Obstructive Coronary Atherosclerosis and IHD: An Elusive LinkMario Marzilli, C. Noel Bairey Merz, William E. Boden, Robert O. Bonow, Paola G. Capozza,
William M. Chilian, Anthony N. DeMaria, Giacinta Guarini, Alda Huqi, Doralisa Morrone,
Manesh R. Patel, William S. Weintraub
The current pathophysiologic model of chronic ischemic heart disease (IHD) focuses on the
identification and removal of obstructive atherosclerotic plaque. Marzilli and colleagues review
several lines of evidence, including poor prognostic impact, suggesting that atherosclerosis is
just one element in a complex multifactorial pathophysiologic process that includes
inflammation, microvascular coronary dysfunction, endothelial dysfunction, thrombosis, and
angiogenesis. They propose a model that shifts the focus away from the epicardial arteries to
the microvasculature and myocardial cells. In this model, all the potential pathological inputs
are considered and addressed with a goal of protecting the cardiomyocytes. An accompanying
commentary by Pepine and Douglas argues that while there is clearly a need to shift to a
multifactorial model of myocardial ischemia, epicardial stenoses still play an important role.STATE-OF-THE-ART PAPER REVIEW AND COMMENTARY957Rethinking Stable Ischemic Heart Disease: Is This the Beginning of a New Era?Carl J. Pepine, Pamela S. Douglas
The authors disagree with the authors’ attempt to debunk the “direct” relationship between
obstructive coronary artery disease and ischemic heart disease, rather than recognizing that
there is, in fact, a direct relationship but that this relationship is not the only pathway to
myocardial ischemia. Thus, a more enlightened position would be that obstruction does not
always imply presence of ischemia and absence of obstruction does not always imply absence
of ischemia. The authors agree that there is clearly a need to shift to a multifactorial model
highlighting causes and mechanisms in pathoanatomy involved in pathogenesis of myocardial
ischemia. Otherwise, they risk being like the drunk, searching for lost keys under the
streetlight, simply because the light is better.(continued on page A-26)
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APREVENTIVE CARDIOLOGY
960mproving the Ability to Identify Individuals
With Silent Heart Disease Using BiomarkersM. Adnan Nadir, Sushma Rekhraj, Li Wei, Tiong K. Lim, John Davidson, Thomas M. MacDonald,
Chim C. Lang, Ellie Dow, Allan D. Struthers
One possible way to improve primary prevention of cardiovascular events is to identify those
patients who already harbor silent cardiac target organ damage (cTOD), i.e., myocardial
ischemia, left ventricular hypertrophy, systolic dysfunction, diastolic dysfunction, or left atrial
enlargement. Nadir and colleagues prospectively recruited 300 asymptomatic individuals and
measured high sensitivity cardiac troponin T (hs-cTnT) and B-type natriuretic peptide (BNP)
and then performed transthoracic echocardiography and stress testing. Thirty-four percent of
patients had evidence of cTOD. The area under curve for BNP and hs-cTnT together was
0.81 and 0.82 in men. Pre-screening with BNP  cTnT followed by targeted phenotyping is
orth exploring further as a possible way to improve primary prevention.ditorial Comment: Mark Richards, p. 969VALVULAR HEART DISEASE
971Comparison of Early Anticoagulation Strategies
After Bioprosthetic Aortic Valves in Older PatientsJ. Matthew Brennan, Fred H. Edwards, Yue Zhao, Sean O’Brien, Michael E. Booth, Rachel S. Dokholyan,
Pamela S. Douglas, Eric D. Peterson
Patients receiving aortic valve bioprostheses have an elevated early risk of thromboembolic
events; however, the risks and benefits of short-term anticoagulation are not clear. Brennan
and colleagues pooled data from over 25,000 elderly patients who received aortic valve
bioprostheses. The 3 most common discharge anticoagulation strategies were aspirin-only
(49%), warfarin-only (12%), and warfarin plus aspirin (23%). In this nonrandomized sample,
those treated with warfarin plus aspirin had a lower adjusted risk of death (relative risk [RR]:
0.80) and embolic events (RR: 0.52), but a higher risk of bleeding (RR: 2.80) compared to
aspirin-only. Warfarin-only patients had similar risks as aspirin-only. These results will help
to clarify the risks and benefits of short-term anticoagulation with warfarin in addition to
aspirin after bioprosthetic aortic valve replacement.
Editorial Comment: Richard P. Whitlock, John W. Eikelboom, p. 978(continued on page A-27)









EHEART RYHTHM DISORDERS981DT Probably Not Necessary for New ICD ImplantationMichele Brignole, Eraldo Occhetta, Maria Grazia Bongiorni, Alessandro Proclemer, Stefano Favale,
Saverio Iacopino, Leonardo Calo`, Antonello Vado, Gianfranco Buja, Giosue` Mascioli, Fabio Quartieri,
assimo Tritto, Umberto Parravicini, Antonio Castro, Corrado Tomasi, Giovanni Quinto Villani,
atteo Giuseppe D’Acri, Catherine Klersy, Maurizio Gasparini, on the behalf of the SAFE-ICD Study
nvestigators
Although a defibrillation test (DT) is considered a standard procedure during cardioverter
defibrillator implantation, its usefulness has not been definitively proven. The SAFE-ICD
Study is a prospective observational study designed to evaluate the outcome of 2 strategies:
performing (DT) versus not performing (DT) during de novo implantable cardioverter
efibrillator (ICD) implants. Subjects were enrolled at 41 Italian centers and followed for 24
onths; subjects were not randomized but underwent the standard protocol for their
nstitution. The primary endpoint was a composite of severe complications during ICD
mplant and sudden cardiac death or resuscitation at 2 years. There was no difference in the
rimary endpoint or mortality. These data show neither harm nor benefit for DT testing after
CD implantation.ditorial Comment: N. A. Mark Estes III, p. 988HEART RYHTHM DISORDERS990Modeling of CPVT With Patient-Specific Pluripotent Stem CellsIlanit Itzhaki, Leonid Maizels, Irit Huber, Amira Gepstein, Gil Arbel, Oren Caspi, Liron Miller,
Bernard Belhassen, Eyal Nof, Michael Glikson, Lior Gepstein
Mutations in the cardiac ryanodine receptor (RyR) gene are responsible for catecholaminergic
polymorphic ventricular tachycardia (CPVT). Itzhaki and colleagues sought to establish a
patient-specific model of CPVT using human-induced pluripotent stem cells (hiPSCs).
Dermal fibroblasts were obtained from a CPVT patient and used to generate the CPVT-
hiPSCs, which were then coaxed to differentiate into the cardiac lineage. Intracellular
electrophysiological recordings confirmed the development delayed-afterdepolarizations
(DADs) in 69% of the CPVT-hiPSCs-cardiomyocytes compared with 11% in healthy-
control cardiomyocytes. This study highlights the potential of hiPSCs for studying inherited
arrhythmogenic syndromes.
Editorial Comment: Massimiliano Gnecchi, Peter J. Schwartz, p. 1001(continued on page A-28)
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Woo-Sup Shim, Eun Young Choi, Sang Yun Lee, Jae Suk Baek
Relief of right ventricular (RV) outflow tract obstruction in tetralogy of Fallot (TOF) or
similar physiology often results in pulmonary regurgitation (PR). The resultant chronic
volume overload can lead to RV dilation, biventricular dysfunction, heart failure symptoms,
arrhythmias, and sudden death. Pulmonary valve replacement (PVR) can lead to substantial
decreases or normalization of RV volumes, but the bioprosthetic valves have a finite lifespan.
Lee and colleagues reviewed 170 patients who underwent PVR, many of whom had pre- and
post-operative cardiac magnetic resonance imaging (MRI), to define the optimal timing of
PVR. Subjects with pre-operative RV end-systolic volume index (ESVI) 80 ml/m2 were at
increased for poor outcomes.Editorial Comment: Kathryn W. Holmes, p. 1015CONGENITAL HEART DISEASE101818 Years of the Fontan Operation at a Single InstitutionLindsay S. Rogers, Andrew C. Glatz, Chitra Ravishankar, Thomas L. Spray, Susan C. Nicolson, Jack Rychik,
Christina Hayden Rush, J. William Gaynor, David J. Goldberg
This is a single-center, retrospective review of 771 patients who underwent Fontan palliation
from 1992 to 2009. Patients were divided into 3 eras dictated by shift in clinical practice.
Overall mortality was 3.5%, but only 1% since 1996. The age at Stage II palliation decreased
from Era 1 to Era 3, while age at Fontan increased. The proportion of patients with
prolonged hospitalization decreased substantially after Era 1. Short-term mortality after
Fontan operation in the modern era is rare, and morbidity is also improving.
